Atomoxetine
- Generic Name
- Atomoxetine
- Brand Names
- Strattera
- Drug Type
- Small Molecule
- Chemical Formula
- C17H21NO
- CAS Number
- 83015-26-3
- Unique Ingredient Identifier
- ASW034S0B8
- Background
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associat...
- Indication
Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Associated Therapies
- -
Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous Noradrenaline
- Conditions
- Interventions
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2013-02-20
- Lead Sponsor
- University of Turku
- Target Recruit Count
- 8
- Registration Number
- NCT01794975
- Locations
- 🇫🇮
Clinical Research Services Turku (CRST) / Turku PET Centre, Turku, Finland
Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)
- Conditions
- Interventions
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 30
- Registration Number
- NCT01738191
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
A Study to Examine the Progression of Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment and to Analyze Associated Factors
- Conditions
- Interventions
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2015-06-09
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 289
- Registration Number
- NCT01624649
Unraveling the Nature of Impaired Pain Inhibition in Patients With Chronic Whiplash-associated Disorders
- First Posted Date
- 2012-05-18
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Vrije Universiteit Brussel
- Target Recruit Count
- 59
- Registration Number
- NCT01601912
- Locations
- 🇧🇪
Universitair Ziekenhuis Brussel, Brussels, Belgium
Clinical Efficacy of Atomoxetine for Methamphetamine Dependence
- First Posted Date
- 2012-03-19
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 20
- Registration Number
- NCT01557569
- Locations
- 🇺🇸
UAMS, Psychiatric Research Institute, Center for Addiction Research, Little Rock, Arkansas, United States
Effects of Atomoxetine in Mild Cognitive Impairment
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Emory University
- Target Recruit Count
- 39
- Registration Number
- NCT01522404
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
Cognitive Effects of Atomoxetine in Humans: Genetic Moderators
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Yale University
- Target Recruit Count
- 35
- Registration Number
- NCT01498549
- Locations
- 🇺🇸
Department of Veterans Affairs, West Haven, Connecticut, United States
Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline
- Conditions
- Interventions
- First Posted Date
- 2011-09-16
- Last Posted Date
- 2013-02-18
- Lead Sponsor
- University of Turku
- Target Recruit Count
- 10
- Registration Number
- NCT01435213
- Locations
- 🇫🇮
University of Turku, Clinical Research Services Turku CRST, Turku, Finland
🇫🇮University of Turku, Turku PET Centre, Turku, Finland
Cognitive Decline in Non-demented PD
- First Posted Date
- 2011-04-25
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 9
- Registration Number
- NCT01340885
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD)
- First Posted Date
- 2011-04-20
- Last Posted Date
- 2011-04-20
- Lead Sponsor
- Peking University
- Target Recruit Count
- 100
- Registration Number
- NCT01339286
- Locations
- 🇨🇳
Peking University Sixth Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.